Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
Immunotherapy may prolong survival compared with standard chemotherapy.
Those with NAFLD or NASH and cirrhosis should undergo regular screening.
A recent study found worse survival rates for those living in low-income, low-education and urban areas.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Many people with GI cancers are diagnosed only after the disease has spread through the body, so this test could aid in early detection.
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
Gastrointestinal cancers conference emphasizes patient quality of life.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.